Sfoglia per AUTORE
MORABITO A
Collezione AOU San Luigi di Orbassano

  

Items : 17

2025
AOU San Luigi di Orbassano
AOU Novara

Wakelee H; Garassino M; Peters S; Takada K; Naqash AR; Torri V; Hejleh TA; Ferrara R; Aerts JGJV; Aboubakar Nana F; Dingemans AM; Biello F; Rogado J; Moliner L; Beninato T; Lo Russo G; Servetto A; Mezquita L; Gorría T; Minuti G; Bennati C; Tonini G; Cortinovis DL; Agustoni F; Majem M; Baena J; Macerelli M; Monnet I; O'Reilly D; et alii...

Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2023 Jul;187:174-184. doi: 10.1016/j.ejca.2023.03.027. Epub 2023 Mar 30.
2023
AOU San Luigi di Orbassano

Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C;

2022
AOU San Luigi di Orbassano

Peters S; Dziadziuszko R; Morabito A; Felip E; Gadgeel SM; Cheema P; Cobo M; Andric Z; Barrios CH; Yamaguchi M; Dansin E; Danchaivijitr P; Johnson M; Novello S; Mathisen MS; Shagan SM; Schleifman E; Wang J; Yan M; Mocci S; Voong D; Fabrizio DA; Shames DS; Riehl T; Gandara DR; Mok T;

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.
2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Russo A; Porzio G; Tiseo M; Russano M; Ficorella C; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Metro G; Migliorino MR; Passiglia F; Ricciardi S; Zoratto F; Pecci F; Di Marino P; Mansueto G; De Tursi M; Tuzi A; Gori S; Della Gravara L; Macerelli M; Rastelli F; Chiari R; Gelibter A; Marchetti P; Antonuzzo L; Mazzoni F; et alii...

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Jan;33(1):57-66. doi: 10.1016/j.annonc.2021.09.017. Epub 2021 Oct 5.
2022
AO Cuneo
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Scagliotti GV; Porcu L; Manegold C; Monica V; Wiest G; Irtelli L; Caffo O; Dickgreber NJ; Follador A; Pedrazzoli P; Bearz A; Griesinger F; Folprecht G; Schmid-Bindert G; Reck M; Chiari R; Gregorc V; Santo A; Morabito A; Schena M; Valmadre G; Borra G; Ceribelli A; Kropf-Sanchen C; Stoelben E; Cauchi C; Colantonio I; Geissler M; Meyer A; et alii...

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2022 Dec;17(12):1404-1414. doi: 10.1016/j.jtho.2022.08.018. Epub 2022 Sep 10.
2022
AOU San Luigi di Orbassano

Ou SI; Nishio M; Ahn MJ; Mok T; Barlesi F; Zhou C; Felip E; de Marinis F; Kim SW; Pérol M; Liu G; Migliorino MR; Kim DW; Novello S; Bearz A; Garrido P; Mazieres J; Morabito A; Lin HM; Yang H; Niu H; Zhang P; Kim ES;

2022
AO Cuneo
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Porcu L; Manegold C; Scagliotti GV; Monica V; Wiest G; Irtelli L; Dickgreber NJ; Caffo O; Pedrazzoli P; Bearz A; Folprecht G; Griesinger F; Follador A; Chiari R; Reck M; Morabito A; Santo A; Schmid-Bindert G; Gregorc V; Schena M; Valmadre G; Borra G; Ceribelli A; Kropf-Sanchen C; Stoelben E; Cauchi C; Colantonio I; Geissler M; Meyer A; et alii...

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.
2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Addeo A; Friedlaender A; Banna GL; Di Maio M; Spinelli GP; Russo A; Adamo V; De Filippis M; Metro G; Simona C; Natalizio S; Migliorino MR; Landi L; Ricciardi S; Buti S; Minuti G; Nigro O; Cantini L; Bracarda S; Citarella F; Russano M; Filetti M; Zoratto F; Gori S; De Tursi M; Mansueto G; Rocco D; et alii...

Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without (223)Ra. in Cancer biotherapy & radiopharmaceuticals / Cancer Biother Radiopharm. 2021 Jun;36(5):391-396. doi: 10.1089/cbr.2020.4442. Epub 2021 Mar 25.
2021
ASL Asti
AOU San Luigi di Orbassano

Spada M; Salgarello M; Borsatti E; Pignata S; Zichi C; Masini C; Morabito A; Fanti S; Sbrana A; Donner D; Alongi P; Alongi F; Bortolus R; Facchini G; Tucci M; Baldari S; Pinto C; Costa RP; Galli L; Monari F; Caffo O; Frantellizzi V; De Giorgi U; Lo Re G; Cortesi E; De Vincentis G;

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ? 50%: a multicenter study with external validation. in Journal for immunotherapy of cancer / J Immunother Cancer. 2020 Oct;8(2):e001403. doi: 10.1136/jitc-2020-001403.
2020
AOU San Luigi di Orbassano

Cortellini A; Ricciuti B; Tiseo M; Bria E; Banna GL; Aerts JG; Barbieri F; Giusti R; Cortinovis DL; Migliorino MR; Catino A; Passiglia F; Torniai M; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Rastelli F; Chiari R; Rocco D; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Grossi F; et alii...

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ? 50% and Their Relationship With Clinical Outcomes. in Clinical lung cancer / Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21.
2020
AOU San Luigi di Orbassano

Cortellini A; Friedlaender A; Banna GL; Porzio G; Bersanelli M; Cappuzzo F; Aerts JGJV; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Berardi R; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Inno A; Di Marino P; Mansueto G; Zoratto F; et alii...

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ??50. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May
2020
AOU San Luigi di Orbassano

Cortellini A; Tiseo M; Banna GL; Cappuzzo F; Aerts JGJV; Barbieri F; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Santini D; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; et alii...

Listening understanding and acting (lung): focus on communicational issue in thoracic oncology. in Translational cancer research / Transl Cancer Res. 2019 Jan;8(Suppl 1):S16-S22. doi: 10.21037/tcr.2018.12.32.
2019
AOU San Luigi di Orbassano
AOU Novara

Romano G; Roca E; Morabito A; Montrone M; Minotti V; Migliorino MR; Melotti B; Mazzanti P; Martelli O; Malorgio F; Mancuso G; Landi L; Irtelli L; Gregorc V; Gilli M; Franchina T; Del Conte A; D'Argento E; Cusmai A; Danesi R; Costanzo R; Cortinovis D; Carta A; Bulotta A; Buffoni L; Borra G; Bettini A; Bianco R; Barbieri V; et alii...

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028. Epub 2019 Jun 27.
2019
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Migliaretti G; Pacchiana MV; Critelli R; Manzo A; Metro G; Morelli AM; Ricciardi S; Bria E; Colantonio I; Ciuffreda L; Del Conte A; Ceresoli GL; Pisconti S; Scotti V; Gregorc V; Romano G; Galetta D; Delmonte A; Tiseo M; Costanzo FD; Chiari R; Grossi F; Stura I; Morabito A; Migliorino MR; Capelletto E; Novello S;

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. in Future oncology (London, England) / Future Oncol. 2018 Feb;14(4):353-361. doi: 10.2217/fon-2017-0441. Epub 2017 Nov 14.
2018
AOU San Luigi di Orbassano

Metro G; Passaro A; Lo Russo G; Bonanno L; Giusti R; Gregorc V; Capelletto E; Martelli O; Cecere FL; Giannarelli D; Luciani A; Bearz A; Tuzi A; Scotti V; Tonini G; Galetta D; Carta A; Soto Parra H; Rebonato A; Morabito A; Chiari R; Metro G; Passaro A; Lo Russo G; Bonanno L; Giusti R; Gregorc V; Capelletto E; Martelli O; et alii...

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2016 May;95:73-81. doi: 10.1016/j.lungcan.2016.02.011. Epub 2016 Feb 26.
2016
AOU San Luigi di Orbassano

Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Bria E; Spitaleri G; Rossi A; Novello S;

Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy. in Analytical cellular pathology (Amsterdam) / Anal Cell Pathol (Amst). 2016;2016:4918325. doi: 10.1155/2016/4918325. Epub 2016 Dec 18.
2016
AOU San Luigi di Orbassano

Cavalcanti E; Barchiesi V; Cerasuolo D; Di Paola F; Cantile M; Cecere SC; Pignata S; Morabito A; Costanzo R; Di Maio M; Perrone F;